The FDA clarity and planned IND submission de-risk the lead program; monitor June 2026 IND filing and any additional pipeline updates. The narrower loss and stable cash position provide runway into 2027.
Price Chart
Executive Summary
aTyr Pharma reported Q1 2026 net loss of $10.8M ($0.11/share), narrower than the prior year, and ended the quarter with $68.3M cash. The company reiterated its plan to submit an IND in June 2026 for a Phase 3 study of efzofitimod in pulmonary sarcoidosis following constructive FDA feedback, providing a clear regulatory path forward.
Key Financial Metrics
Key Facts
- Q1 2026 net loss attributable to aTyr was $10.8M ($0.11/share) vs $14.9M ($0.17/share) in Q1 2025
- Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026
- R&D expenses decreased to $7.3M from $11.8M year-over-year
- Plans to submit IND in June 2026 for a new Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease
- Phase 2 EFZO-CONNECT study enrollment on track to complete in first half 2026
Financial Impact
Net loss improved by 27.5% year-over-year; cash burn $15.6M in Q1 2026 vs $14.1M in Q4 2025
Risk Factors
- Clinical trial failure of efzofitimod in Phase 3
- Cash burn may require future dilutive financing
- Regulatory delays or additional FDA requirements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001339970-26-000030 |
| Document: atyr-20260515.htm | 0001339970-26-000030 |
| Document: 0001339970-26-000030-index-headers.html | 0001339970-26-000030 |
| Document: 0001339970-26-000030-index.html | 0001339970-26-000030 |
| Document: 0001339970-26-000030.txt | 0001339970-26-000030 |
| 8-K Data (Synthetic) | 0001339970-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | Press Release | $0.1717 $0.1534 | ▼ −10.66% | ▼ −10.51% | $0.1530 (−10.89%) |
Oct 7, 2026 20d ago | SC 13G/A | $0.2783 $0.1833 | ▼ −34.14% | ▼ −33.16% | $0.1530 (−45.02%) |
Sep 22, 2026 4w ago | Institutional Cluster | $0.3564 $0.3077 | ▲ +13.66% | ▲ +12.48% | $0.1530 (+57.07%) |
Aug 7, 2026 11w ago | 8-K | $0.5289 $0.5189 | ▲ +1.89% | ▲ +1.84% | $0.1530 (+71.07%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.4754 $0.4629 | ▼ −2.63% | ▼ −3.06% | $0.1530 (−67.82%) |
Jun 8, 2026 20w ago | 8-K | $0.4556 $0.4433 | ▲ +2.70% | ▲ +5.11% | $0.1530 (+66.42%) |
Jun 1, 2026 21w ago | 8-K | $0.5200 $0.4560 | ▼ −12.31% | ▼ −9.34% | $0.1530 (−70.58%) |
May 15, 2026 23w ago | 8-K | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1530 (−69.64%) |
May 15, 2026 23w ago | Press Release | $0.5040 $0.4900 | ▼ −2.78% | ▼ −3.74% | $0.1530 (−69.64%) |
May 11, 2026 24w ago | 8-K | $0.5300 $0.5200 | ▼ −1.89% | ▼ −1.96% | $0.1530 (−71.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers